Sudan Loganathan

Stock Analyst at Stephens & Co.

(0)
# 4627
Out of 5,240 analysts
24
Total ratings
30.00%
Success rate
-17.80%
Average return
17 Stocks
Name Action Price Target Current % Upside Ratings Updated
Blueprint Medicines
Reiterates: Overweight
140 140
105.91 32.19% 2 Jan 2, 2025
Elevation Oncology
Reiterates: Overweight
5 5
0.73 584.93% 2 Dec 6, 2024
Actinium Pharma
Reiterates: Overweight
5 5
1.27 293.7% 2 Nov 19, 2024
Catalyst Pharmaceuti...
Initiates Coverage On: Overweight
35
22.19 57.73% 1 Nov 18, 2024
IDEAYA Biosciences
Initiates Coverage On: Overweight
51
23.59 116.19% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Equal-Weight
4
3.9 2.56% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
65
41.17 57.88% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
55
17.74 210.03% 1 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Equal-Weight
25
14.59 71.35% 1 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
6
1.72 248.84% 1 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
30
9.54 214.47% 1 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
13
1.41 821.99% 1 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
23 29
36.33 -20.18% 2 Oct 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
31 31
19.73 57.12% 2 Oct 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
25 25
12.99 92.46% 2 Aug 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
5 5
0.47 963.83% 2 May 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
20
1.9 952.63% 1 May 14, 2024